Cardiac Biomarkers Market Size (2024 - 2029)

Cardiac Biomarkers Market Analysis

The Cardiac Biomarkers Market is expected to register a CAGR of 8.5% during the forecast period.

The market was significantly impacted by the COVID-19 pandemic. According to an NCBI study published in Current Problems in Cardiology in October 2021, in the majority of the complex cases of COVID-19, cardiac injury biomarkers were elevated. This elevation is inversely correlated with the worst outcome. A more reliable tool for predicting case fatalities and outcomes is provided by the evaluation of cardiac biomarkers in combination with markers of other organ damage. Thus, the use of cardiac biomarkers enables the disease management of severely ill patients, thereby impacting the growth of the market during the pandemic period. Also, the demand for cardiac biomarkers is expected to remain intact due to the increasing focus on the diagnosis of cardiovascular diseases during the post-pandemic period, thereby contributing to the growth of the market over the forecast period.

The cardiac biomarker market is driven by the rising burden of cardiovascular diseases, technological advances in cardiac biomarkers, and growing research and development funding. For instance, the British Heart Foundation (BHF) data published in January 2022 reported that in 2021, the most common heart conditions affected globally were coronary (ischemic) heart disease (global prevalence estimated at 200 million), peripheral arterial (vascular) disease (110 million), stroke (100 million), and atrial fibrillation (60 million). The report also mentioned that the prevalence of heart and circulatory diseases in North America was 46 million, in Europe it was 99 million, in Africa it was 58 million, in South America it was 32 million, and in Asia and Australia it was 310 million. Thus, the high prevalence of cardiovascular diseases is expected to drive the demand for early diagnosis and treatment, which may expand the scope of the market studied over the forecast period.

Moreover, the launch of technologically advanced cardiac biomarkers by various market players is also anticipated to boost the market. For instance, in April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology, i.e., high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold-standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP).

Therefore, the rising incidence of cardiovascular diseases among the global population and increasing innovative product launches are expected to drive the growth of the market over the forecast period. However, the stringent regulatory framework is expected to impede the growth of the market over the forecast period.

Cardiac Biomarkers Industry Segmentation

As per the scope of the report, cardiac biomarkers are of great importance in the timely and accurate diagnosis and management of acute coronary syndrome, as well as the prognosis. The Cardiac Biomarkers Market is segmented by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Other Types), Application (Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Other Applications), Location of Testing (Point-of-Care Testing and Laboratory Testing), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD million) for all the above segments.